GlassScriptPhysician profile
Evan N Dickstein
NPI 1942688379
$1,909.03
in general payments reported to CMS, 2019-2025
21 companies · $748 in 2025
The $748 reported for 2025 was more than what 75% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $98.76 · 2022: $171 · 2023: $331 · 2024: $561 · 2025: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,639.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $467.53 | 2021-2025 | |
| Corium, LLC | $247.35 | 2023-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $150.05 | 2022-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $125.72 | 2023-2025 | Dyanavel Xr |
| Lundbeck LLC | $121.71 | 2024-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $101.27 | 2025 | Gardasil 9, Capvaxive, M-M-R II |
| Sage Therapeutics, LLC | $92.82 | 2025 | Zurzuvae |
| Ironshore Pharmaceuticals INC. | $81.47 | 2023-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $68.22 | 2025 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.39 | 2022-2023 | |
| Sunovion Pharmaceuticals INC. | $64.37 | 2021-2022 | |
| Axsome Therapeutics, INC. | $60.99 | 2024-2025 | Auvelity, Sunosi |
| Alk-Abello, INC | $53.34 | 2025 | Neffy, Odactra, Ragwitek |
| Idorsia Pharmaceuticals US INC | $39.87 | 2023-2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $38.50 | 2023-2024 | Trintellix |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $36.03 | 2024-2025 | Flumist Quadrivalent, Airsupra |
| Janssen Pharmaceuticals, INC | $29.23 | 2025 | Spravato |
| Vertical Pharmaceuticals, LLC | $18.92 | 2024 | Relexxii |
| Owp Pharmaceuticals, INC. | $17.16 | 2025 | Subvenite |
| Cranial Technologies, INC | $15.74 | 2024 | Doc Band |
| Sanofi Pasteur INC. | $13.35 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Dickstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.